CA2871778C — Pharmaceutical nanoparticles showing improved mucosal transport
Assigned to Alcon Inc · Expires 2022-09-13 · 4y expired
What this patent protects
Compositions with improved particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions may include modifyin…
USPTO Abstract
Compositions with improved particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions may include modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications.
Drugs covered by this patent
- Lotemax (LOTEPREDNOL ETABONATE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.